Candel Therapeutics Inc

CADL14 Feb 2025
Healthcare
$8.5
+0.02 (+1.64%)
Lowest Today
$8.35
Highest Today
$8.74
Today’s Open
$8.5
Prev. Close
$8.55
52 Week High
$14.3
52 Week Low
$1.34
To Invest in Candel Therapeutics Inc

Candel Therapeutics Inc

Healthcare
CADL14 Feb 2025
+0.02 (+1.64%)
1M
3M
6M
1Y
5Y
Low
$8.35
Day’s Range
High
$8.74
8.35
52 Week Low
$1.34
52-Week Range
52 Week High
$14.3
1.34
1 Day
-
1 Week
+8.8%
1 month return
+10.27%
3 month return
+98.37%
6 month return
+46.31%
1 Year return
+381.92%
3 Years return
+89.55%
5 Years return
-
10 Years return
-
Institutional Holdings
Fidelity Select Biotechnology
8.8
Northpond Ventures, LLC
4.35
BlackRock Inc
2.53
Vanguard Group Inc
2.13
Vanguard Total Stock Mkt Idx Inv
1.95
iShares Russell 2000 ETF
1.31
State Street Corp
1.11

Market Status

Fundamentals
Market Cap
134.29 mln
PB Ratio
30.41
PE Ratio
0
Enterprise Value
368.17 mln
Total Assets
41.2 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Organisation
Candel Therapeutics Inc
Employees
42
Industry
Biotechnology
CEO
Dr. Paul-Peter  Tak FOCIS, M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step